Logo image of CDIO

CARDIO DIAGNOSTICS HOLDINGS (CDIO) Stock Fundamental Analysis

NASDAQ:CDIO - Nasdaq - US14159C1036 - Common Stock - Currency: USD

3.99  -0.22 (-5.23%)

After market: 3.99 0 (0%)

Fundamental Rating

2

Overall CDIO gets a fundamental rating of 2 out of 10. We evaluated CDIO against 560 industry peers in the Biotechnology industry. The financial health of CDIO is average, but there are quite some concerns on its profitability. CDIO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CDIO has reported negative net income.
In the past year CDIO has reported a negative cash flow from operations.
CDIO had negative earnings in each of the past 5 years.
CDIO had negative operating cash flow in 4 of the past 5 years.
CDIO Yearly Net Income VS EBIT VS OCF VS FCFCDIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M

1.2 Ratios

CDIO has a Return On Assets (-47.67%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -51.46%, CDIO is in the better half of the industry, outperforming 64.29% of the companies in the same industry.
Industry RankSector Rank
ROA -47.67%
ROE -51.46%
ROIC N/A
ROA(3y)-113.75%
ROA(5y)-106.63%
ROE(3y)-159.76%
ROE(5y)-310.78%
ROIC(3y)N/A
ROIC(5y)N/A
CDIO Yearly ROA, ROE, ROICCDIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

CDIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDIO Yearly Profit, Operating, Gross MarginsCDIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

5

2. Health

2.1 Basic Checks

CDIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
CDIO has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, CDIO has an improved debt to assets ratio.
CDIO Yearly Shares OutstandingCDIO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
CDIO Yearly Total Debt VS Total AssetsCDIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

CDIO has an Altman-Z score of 1.49. This is a bad value and indicates that CDIO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CDIO (1.49) is better than 70.89% of its industry peers.
CDIO has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
CDIO's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. CDIO outperforms 41.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 1.49
ROIC/WACCN/A
WACC9.44%
CDIO Yearly LT Debt VS Equity VS FCFCDIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

A Current Ratio of 19.49 indicates that CDIO has no problem at all paying its short term obligations.
With an excellent Current ratio value of 19.49, CDIO belongs to the best of the industry, outperforming 93.93% of the companies in the same industry.
CDIO has a Quick Ratio of 19.49. This indicates that CDIO is financially healthy and has no problem in meeting its short term obligations.
CDIO has a better Quick ratio (19.49) than 93.93% of its industry peers.
Industry RankSector Rank
Current Ratio 19.49
Quick Ratio 19.49
CDIO Yearly Current Assets VS Current LiabilitesCDIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for CDIO have decreased strongly by -317.33% in the last year.
CDIO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -36.22%.
EPS 1Y (TTM)-317.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-385%
Revenue 1Y (TTM)-36.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%5800.82%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 2032.01% on average over the next years. This is a very strong growth
EPS Next Y-224.15%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year854.55%
Revenue Next 2Y2032.01%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
CDIO Yearly Revenue VS EstimatesCDIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
CDIO Yearly EPS VS EstimatesCDIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CDIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CDIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDIO Price Earnings VS Forward Price EarningsCDIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDIO Per share dataCDIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CDIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIO DIAGNOSTICS HOLDINGS

NASDAQ:CDIO (5/30/2025, 5:20:01 PM)

After market: 3.99 0 (0%)

3.99

-0.22 (-5.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-12 2025-08-12
Inst Owners4.93%
Inst Owner Change-1.31%
Ins Owners4.52%
Ins Owner Change0%
Market Cap6.94M
Analysts82.86
Price TargetN/A
Short Float %2.71%
Short Ratio1.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)65.41%
Min EPS beat(2)47.17%
Max EPS beat(2)83.66%
EPS beat(4)4
Avg EPS beat(4)54.63%
Min EPS beat(4)41.18%
Max EPS beat(4)83.66%
EPS beat(8)6
Avg EPS beat(8)17.12%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)831.37%
Min Revenue beat(2)-80.39%
Max Revenue beat(2)1743.14%
Revenue beat(4)1
Avg Revenue beat(4)368.94%
Min Revenue beat(4)-93.86%
Max Revenue beat(4)1743.14%
Revenue beat(8)1
Avg Revenue beat(8)140.03%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-2900%
EPS NQ rev (3m)-2900%
EPS NY rev (1m)-2900%
EPS NY rev (3m)-2900%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 348.87
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB 0.65
EV/EBITDA N/A
EPS(TTM)-3.13
EYN/A
EPS(NY)-7.65
Fwd EYN/A
FCF(TTM)-3.18
FCFYN/A
OCF(TTM)-2.97
OCFYN/A
SpS0.01
BVpS6.54
TBVpS6.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.67%
ROE -51.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-113.75%
ROA(5y)-106.63%
ROE(3y)-159.76%
ROE(5y)-310.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 102.22%
Cap/Sales 1918.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.49
Quick Ratio 19.49
Altman-Z 1.49
F-Score5
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)419.33%
Cap/Depr(5y)421.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-317.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-385%
EPS Next Y-224.15%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-36.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%5800.82%
Revenue Next Year854.55%
Revenue Next 2Y2032.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y39.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.22%
OCF growth 3YN/A
OCF growth 5YN/A